Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D

BACKGROUND: This study assessed the antitumor activity and safety of durvalumab plus tremelimumab combined with neoadjuvant chemotherapy (NAC) in patients newly diagnosed with advanced ovarian cancer. Here, we report the primary endpoint of the original cohort of the KGOG 3046/TRU-D study. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Junsik, Lee, Jung Bok, Lim, Myong Cheol, Kim, Byoung-Gie, Kim, Jae-Weon, Kim, Sunghoon, Choi, Chel Hun, Kim, Hee Seung, Park, Sang Yoon, Lee, Jung-Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603354/
https://www.ncbi.nlm.nih.gov/pubmed/37865397
http://dx.doi.org/10.1136/jitc-2023-007444

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603354/
https://www.ncbi.nlm.nih.gov/pubmed/37865397
http://dx.doi.org/10.1136/jitc-2023-007444

Ejemplares similares